Access
To read this story in full you will need to login or make a payment (see right).
Correspondence
Nature Medicine 15, 602 (2009)
doi:10.1038/nm0609-602a
Reply to 'Mesenchymal stem cells: another anti-inflammatory treatment for sepsis?'
Krisztián Németh1, Asada Leelahavanichkul2, Peter S T Yuen2, Balázs Mayer1, Alissa Parmelee1, Kent Doi2, Pamela G Robey1, Kantima Leelahavanichkul1, Beverly H Koller4, Jared M Brown5, Xuzhen Hu2, Ivett Jelinek3, Robert A Star2 & Éva Mezey1
- Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, Bethesda, Maryland, USA.
- Renal Diagnostics and Therapeutics Unit, National Institute of Diabetes and Digestive Kidney Diseases, Bethesda, Maryland, USA.
- Experimental Immunology Branch, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA.
- Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
- Department of Pharmacology and Toxicology, East Carolina University, Greenville, North Carolina, USA.
Correspondence to: Éva Mezey1 e-mail: mezeye@mail.nih.gov
A typical bench-to-bedside path in medicine is to first discover specific targets using basic science and then develop therapeutic agents that are tested clinically. In the field of bone marrow stromal cells (BMSCs; also referred to as mesenchymal stem cells or MSCs), this course was reversed—running from bedside to bench.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Bone marrow stromal cells attenuate sepsis via prostaglandin E 2 ?dependent reprogramming of host macrophages to increase their interleukin-10 productionNature Medicine Article (01 Jan 2009)
